0.00Open0.18Pre Close0 Volume64 Open Interest30.00Strike Price0.00Turnover153.55%IV64.47%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier15DDays to Expiry0.18Extrinsic Value100Contract SizeAmericanOptions Type0.0784Delta0.0256Gamma101.94Leverage Ratio-0.0271Theta0.0005Rho7.99Eff Leverage0.0055Vega
Grail Stock Discussion
Larger Image: tradingview.com...
$Grail (GRAL.US)$
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
No comment yet